TrialInvestigational new drugs2022

A pharmacokinetic study to comparatively evaluate the bioequivalence and safety of a humanized recombinant monoclonal antibody targeting human epidermal growth factor receptor-2 with the reference Herceptin in healthy Chinese subjects.

Fangfang Ding et al.PubMed ↗Publisher ↗

No numbers read from the abstract.